Steris agrees to buy Xodus Medical for $2.1 billion

By Public Technologies
  • Steris reached a definitive agreement to buy Xodus Medical, a Pennsylvania-based specialty surgical products maker, for USD 2.1 billion at closing.
  • Cash tax benefits with an estimated net present value of about USD 300 million imply a net purchase price of about USD 1.8 billion.
  • An earnout of up to USD 150 million is tied to specified post-closing performance targets in calendar 2028.
  • Xodus expects about USD 245 million of 2026 revenue, with adjusted EBIT of about USD 135 million.
  • Closing is targeted by Dec. 31, 2026; financing is expected to be primarily debt-funded.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Steris plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120800PRIMZONEFULLFEED9843616) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.